Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

By D. Kubitza, M. Becka, G. Wensing, B. Voith, M. Zuehlsdorf. European Journal of Clinical Pharmacology, 2005

662 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/2f681a3c83db13ce9ee754ae98b7ced3373a67e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Halperin
2. Robert M. Califf

In Internal Medicine

1. J. Halperin

Citations in the corpus

• Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. (2011, background): “A single dose of rivaroxaban inhibits thrombin generation for 24 h and prolongs the pro-thrombin time in a dose-dependent manner.(6,19) In prior studies of prophylaxis of venous thromboembolism, once-daily and twice-daily regimens differed only in rivaroxaban trough concentrations, not total exposur”